OLE Study of Carbetocin Nasal Spray for the Treatment of Hyperphagia in Prader-Willi Syndrome
This study is investigating a nasal spray called carbetocin for people aged 5 to 30 with Prader-Willi Syndrome (PWS). People with PWS often experience excessive hunger, called hyperphagia. This study is an extension of a previous one, focusing on the long-term safety and whether participants can tolerate the spray over an extended period. Researchers want to understand if daily use of the carbetocin nasal spray (3.2 mg, three times a day) helps manage this challenging symptom. Participants will be those who have already completed the initial study. The aim is to gather more information on its effects when used for a longer time.
एक नजर में
यह अध्ययन किस बारे में है?
This study is known as an Open-Label Extension (OLE) study. This means that everyone taking part will receive the carbetocin nasal spray, and both they (and their caregivers) and the study doctors will know what treatment they are receiving. It's designed to follow on from an earlier study where some participants might have received a placebo (a dummy spray with no active medicine) instead of carbetocin. This open-label format allows researchers to look closely at the medication's longer-term effects.
The main goal of this particular study is to see how safe the carbetocin nasal spray is when used over a longer period, and how well people can tolerate it. 'Tolerability' refers to how comfortable people are with the treatment and whether they experience any side effects. Researchers will be monitoring participants closely for any unexpected reactions or difficulties with using the spray.
By gathering information on long-term safety and tolerability, this study helps us understand more about carbetocin as a potential treatment for the intense, constant hunger (hyperphagia) experienced by individuals with Prader-Willi Syndrome. This condition can significantly impact daily life, and finding safe and effective ways to manage it is very important.
मुख्य निष्कर्ष
- Focuses on long-term safety and tolerability of carbetocin nasal spray.
- For individuals aged 5-30 with Prader-Willi Syndrome.
- Participants must have completed a previous study (ACP-101-302).
- Aims to help manage excessive hunger (hyperphagia).
- Requires active involvement of a caregiver.
- All participants will receive the active carbetocin treatment.
कौन पात्र हो सकता है?
This study is for individuals aged between 5 and 30 years old who have Prader-Willi Syndrome. To be considered, you must have already successfully completed a previous study involving carbetocin (Study ACP-101-302) and met all the entry rules for that initial study. Your doctor would also need to believe that you would benefit from continuing to receive the carbetocin treatment for a longer time.
You would also need to live with a caregiver who is willing and able to understand and follow all the study procedures and attend all scheduled appointments. This is important to ensure the study runs smoothly and safely for everyone involved.
There are certain health conditions that would prevent someone from joining, such as a history of stroke, serious brain injury, epilepsy, or frequent severe migraines. If you have active severe mental health symptoms, or a history of significant mental health issues like psychosis or suicide attempts, you would not be able to participate. Also, if you have certain heart conditions or have had problems tolerating the study medication or procedures in the previous study, you might not be suitable.
क्या यह अध्ययन आपके लिए उपयुक्त हो सकता है?
यह देखने के लिए इन त्वरित प्रश्नों का उत्तर दें कि क्या आप पात्र हो सकते हैं। यह केवल एक मार्गदर्शिका है — अंतिम निर्णय शोध टीम द्वारा लिया जाता है।.
- Are you between 5 and 30 years old?
- Do you have Prader-Willi Syndrome?
- Have you completed the previous ACP-101-302 study?
- Does your doctor think you might benefit from continuing this treatment?
- Do you live with a caregiver who can help you with the study?
भागीदारी में क्या शामिल है?
If you join this study, you will continue to use the carbetocin nasal spray three times a day. You and your caregiver will need to attend regular appointments at the study clinic. These visits will involve health checks, such as measuring your vital signs (like blood pressure and heart rate), and ECGs (heart rhythm tests) to monitor how your heart is doing. The study team will also be asking about any side effects you might experience and how well you are managing with the nasal spray. The exact total duration of your participation will depend on the study design, but it is an open-label extension, meaning it's designed for long-term follow-up for those who completed the initial study.
संभावित जोखिम और लाभ
स्थान (30)
- Children's of Alabamaसत्यापित पोस्टकोडबर्मिंघम, संयुक्त राज्य अमेरिका
- Phoenix Children's Hospitalसत्यापित पोस्टकोडफीनिक्स, संयुक्त राज्य अमेरिका
- University of California Irvineसत्यापित पोस्टकोडऑरेंज, संयुक्त राज्य अमेरिका
- Stanford University School of Medicineसत्यापित पोस्टकोडपैलो आल्टो, संयुक्त राज्य अमेरिका
- Rady Children's Hospital San Diegoसत्यापित पोस्टकोडसैन डिएगो, संयुक्त राज्य अमेरिका
- चिल्ड्रन हॉस्पिटल कोलोराडोसत्यापित पोस्टकोडऑरोरा, संयुक्त राज्य अमेरिका
- Ann & Robert H. Lurie Children's Hospital of Chicagoसत्यापित पोस्टकोडशिकागो, संयुक्त राज्य अमेरिका
- आयोवा विश्वविद्यालयसत्यापित पोस्टकोडआयोवा सिटी, संयुक्त राज्य अमेरिका
- बोस्टन चिल्ड्रन हॉस्पिटलसत्यापित पोस्टकोडबोस्टन, संयुक्त राज्य अमेरिका
- Children's Mercy Kansas Cityसत्यापित पोस्टकोडकैनसस सिटी, संयुक्त राज्य अमेरिका
- SSM Health/Saint Louis Universityसत्यापित पोस्टकोडसेंट लुइस, संयुक्त राज्य अमेरिका
- Maimonides Medical Centerसत्यापित पोस्टकोडBrooklyn, United States
सामान्य प्रश्न
What is Carbetocin?
Carbetocin is a medication being studied in a nasal spray form for people with Prader-Willi Syndrome.
What is 'Hyperphagia'?
Hyperphagia is a medical term for excessive, insatiable hunger, which is a common and challenging symptom for people with Prader-Willi Syndrome.
इस अध्ययन में कौन शामिल हो सकता है?
This study is for individuals aged 5-30 with Prader-Willi Syndrome who have already finished a specific previous study (ACP-101-302).
Will I know if I'm getting the active medicine?
Yes, this is an 'open-label' study, meaning everyone, including you and the study team, will know you are receiving the carbetocin nasal spray.
इस अध्ययन का मुख्य उद्देश्य क्या है?
The main purpose is to evaluate the long-term safety and how well people can tolerate the carbetocin nasal spray for Prader-Willi Syndrome.
और अधिक जानने के लिए कैसे पता करें
किसी अध्ययन में भाग लेने का निर्णय लेने से पहले हमेशा अपने जीपी या विशेषज्ञ से बात करें।.
भाग लेने में रुचि रखते हैं?
चर्चा
समुदाय चर्चा
हमारे फोरम द्वारा संचालित community.patient.info. कृपया सम्मानजनक रहें — यह चिकित्सा सलाह नहीं है।.